Search results
Feb 9, 2023 · The accompanying schedules include additional details on sales performance by product categories and segments. For full-year 2022, net income (loss) attributable to Baxter totaled ($2.4 billion), or ($4.83) per diluted share on a U.S. GAAP basis.
Feb 17, 2022 · Full-Year Financial Results. Baxter's 2021 worldwide sales totaled $12.8 billion, an increase of 10% on a reported basis, 7% on a constant currency basis and 5% on an operational basis.
2022 Financial Outlook For full-year 2022: Baxter now expects U.S. GAAP earnings of $2.35 to $2.43 per diluted share and adjusted earnings, before special items, of $4.12 to $4.20 per diluted share. The company expects sales growth of 23% to 24% on a reported basis, 25% to 26% on a constant
Apr 28, 2022 · Baxter expects full-year 2022 sales growth of 23% to 24% on a reported basis, 25% to 26% on a constant currency basis and approximately 3% on an operational basis. Baxter expects full-year U.S. GAAP EPS of $2.35 to $2.43 and adjusted EPS of $4.12 to $4.20.
Feb 9, 2023 · Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2022, and provided its financial guidance for full-year and first-quarter 2023.
Feb 17, 2022 · For full-year 2021, net income attributable to Baxter totaled $1.3 billion, or $2.53 per diluted share, increasing 19% on a U.S. GAAP basis compared to the prior year.
People also ask
What will Baxter's earnings look like in 2022?
What was Baxter's net income in 2021?
How much did Baxter sell in 2021?
What does Baxter expect in 2022?
What is Baxter's financial outlook for 2023?
What does Baxter expect in 2023?
Feb 11, 2023 · Key Financial Results. Revenue: US$15.1b (up 18% from FY 2021). Net loss: US$2.43b (down by 290% from US$1.28b profit in FY 2021). US$4.83 loss per share (down from US$2.56 profit in FY...
